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Summary
AIMS: Recurrent glioblastoma (GBM) is a disease with
poor prognosis. Although several therapeutic approaches
such as chemotherapy, irradiation or surgery have been
investigated, there is no established standard therapy. A
recent survey among Swiss neuro-oncology centres has
shown considerable controversy in the treatment recom-
mendations for any specific scenario of recurrent GBM. In
view of the cost differences of the available treatment al-
ternatives, the aim of our study was assess the financial
impact of different institutional therapeutic strategies for
recurrent GBM in Switzerland.
METHODS: We created a decision analytic model for
each of the eight centres participating in the initial study
with a centre-specific treatment algorithm to evaluate the
average treatment cost per patient. The probability of deci-
sion criteria was varied by univariate and probabilistic sen-
sitivity analysis over a wide range to account for the high
level of uncertainty. Treatment costs were calculated from
the perspective of the Swiss healthcare payer.
RESULTS: Mean treatment costs per patient calculated on
the basis of the institutional treatment algorithms ranged
from CHF 13,748 to CHF 22,072 depending on the prob-
ability of individual decision criteria. The most influential
decision factors for the mean treatment costs were the
probability of fit patients and the proportion of patients
with resectable tumour recurrences. There was a signifi-
cant correlation between the complexity of treatment algo-
rithms in a centre and the resulting mean treatment costs.
CONCLUSIONS: Institutional treatment algorithms can be
used to estimate the average treatment costs per patient,
which are, however, highly sensitive to probability changes
of individual decision criteria. Our study demonstrates a
high variability in treatment costs for recurrent GBM
among eight Swiss neuro-oncology centres based on indi-
vidual institutional treatment algorithms.
Keywords: glioblastoma, oncology, treatment algorithm,
health economics, decision making, neuro-oncology
Introduction
Glioblastoma multiforme (GBM) is the most common pri-
mary brain tumour in adults, with an annual incidence
of about three per 100,000 persons [1]. Despite recent
progress in multimodality treatment [2, 3] and molecular
classification [4], its overall prognosis remains poor with
a median survival of 15 months for patients receiving
surgery followed by chemoradiation and temozolomide
therapy [2]. Despite extensive surgery and completion of
adjuvant therapy, the vast majority of patients will experi-
ence tumour recurrence [5].
There is currently no standard therapy for recurrent GBM,
although several approaches have been investigated in
clinical trials [6, 7].
Temozolomide, which has become standard-of-care for pa-
tients receiving long-course chemoradiation in the adju-
vant setting [2], has been investigated in various treatment
schedules for recurrent glioblastoma without clear benefit
with dose-intensified schedules [6, 8, 9]. Alternatively, ni-
trosoureas such as lomustine or fotemustine, as well as the
monoclonal antibody bevacizumab targeting the vascular
endothelial growth factor-A, have been tested in recurrent
GBM [6, 10, 11].
Local therapies such as re-irradiation and repeat surgery
have been used for recurrent GBM with controversial re-
sults [12, 13]. More extensive tumour resection has been
associated with improved survival in some studies [14, 15],
but no association between repeat surgery at recurrence
and improved progression-free or overall survival could be
evidenced in a pooled analysis of eight prospective Euro-
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pean Organisation for Research and Treatment of Cancer
(EORTC) trials [16]. Retrospective data support the use of
re-irradiation of recurrent glioma in selected patients, but
prospective data on this approach are still lacking [13, 17].
Overall, the deduction of obvious treatment recommenda-
tions from the available clinical trials and patient series is
hampered by small sample sizes, the lack of control arms
and potential selection bias [6, 18].
In view of the lack of an evidence-based standard therapy,
we conducted a survey in 2015 among eight Swiss neuro-
oncology centres in order to determine consensus and con-
troversies in their treatment recommendations for any sce-
nario of recurrent GBM [19] using the objective consensus
methodology [20]. We found a range of treatment recom-
mendations implemented based on a variety of decision
criteria, with barely any consensus among centres [19].
Health economics in GBM are a subject of rising interest,
as in many other cancers [21], but there is only limited
knowledge on cost effectiveness and other economic as-
pects of different therapies for recurrent glioblastoma [22,
23]. The aim of this study was therefore to deduce the av-
erage treatment costs for recurrent GBM from previously
assessed institutional treatment decision algorithms [19] in
order to assess the financial impact of institutional thera-
peutic strategies in Switzerland.
Materials and methods
The health economics analysis was based on a recent re-
view of treatment algorithms for recurrent GBM among
eight Swiss neuro-oncology centres [19]. We investigated
decision criteria for re-treatment and therapeutic pathways
using the objective consensus methodology [20] in order to
determine consensus and controversies by means of an au-
tomatic software-based comparison of individual decision
trees. The following decision criteria were named: patient
fitness, the presence of a symptomatic recurrence, unifo-
cal recurrence, lesion size, time of recurrence, resectabil-
ity, O6-methylguanine DNA methyltransferase (MGMT)
methylation status. Similar criteria were fused into new
categories with the agreement of all centres to increase
comparability [19]. For instance, “patient fitness” was a
combination of “age”, “performance status” and “co-mor-
bidities” without fixed cut-off values. We identified a total
of 16 different treatment recommendations, which resulted
in a variety of up to six different treatment recommenda-
tions among the eight centres for a specific clinical situa-
tion of tumour recurrence. Areas of consensus were iden-
tified in only a few situations, such as in the
recommendation of best supportive care for unfit patients.
Recommendations supported by the majority of centres
were bevacizumab for inoperable, large early recurrences
with unmethylated MGMT promoter status, and temozolo-
mide for fit inoperable MGMT-promoter-methylated late
recurrences. There was no majority recommendation for
any other scenario [19].
In order to estimate minimum, maximum and average
costs per patient given the treatment pathways for each
centre, a decision analytic model was built using the
TreeAge Pro 2017 software (Tree-Age Software,
Williamstown, MA). For every single centre the treatment
pathways for patients, depending on several serial clinical
criteria and resulting in various treatment choices, were de-
veloped based on previously published decision tree data
[19].
Probabilities for decision criteria were not available from
the literature or real clinical data, therefore in the base case
analysis all decision probabilities were set to 0.5. Costs for
treatments were assessed from the Swiss healthcare pay-
er perspective based on the Swiss outpatient tariff (Tarmed
[24]), the Swiss inpatient tariff (SwissDRG [25]) or the
Swiss drug price list [26] that were valid at the time of
the original study [19], and the number of treatment cy-
cles according to the literature based on an average patient
with a body surface [10, 27] of 1.77 m2 and a weight of 70
kg (see table 1 below). Treatment costs for temozolomide
chemotherapy for recurrent GBM were calculated based on
a schedule of 200 mg/m2 on days 1–5 of a 28-day cycle,
which has become a widely accepted schedule in Switzer-
land in view of the lack of clear benefit of more dose-inten-
sified schedules [6]. Treatment costs of bevacizumab were
based on a 2-weekly administration of 10 mg/kg/m2 with a
median of six administered cycles and of lomustine on ad-
ministration of single dose of 90–110 mg/m2 with a median
duration of one cycle [10].
As there is no established schedule for re-irradiation, we
calculated costs based either on a 5-fraction course of
stereotactic radiotherapy or a 15-fraction course of hy-
pofractionated radiotherapy, which corresponds well to
current practice [13]. Radiotherapy costs were assessed
as an outpatient procedure according to the Swiss outpa-
tient tariff [24]. Costs for hypofractionated radiotherapy or
stereotactic radiotherapy were calculated based on the in-
dividual institutional recommendation [19] of each centre.
Surgery costs were based on the inpatient costs according
to the average Swiss disease-related group (DRG) for brain
tumour resection [25].
On the basis of our institutional practice, costs for clinical
controls, imaging and supportive medication were added to
each treatment strategy (see table 1). End-of-life care was
considered to be equal in all treatment strategies and was
not included into the analysis. Potential third-line therapies
or costs of treatment of side effects were not included into
the analysis because of insufficient data.
All tariffs were calculated with the version valid in May
2017. Costs were not discounted owing to the poor prog-
nosis of the patient population investigated.
We did not have clinical data from all centres concerning
the frequency of specific patient and tumour characteristics
that influenced treatment decision making [19], such as pa-
tient performance (fit vs unfit), MGMT promoter methy-
lation or resectability. Therefore, we performed a series of
sensitivity analyses to test a wide variety of these factors
and their impact on treatment costs. Univariate sensitivity
analysis was used to test for the effect on costs of the
probabilities in a range of 0–1 for all decision steps. A
probabilistic sensitivity analysis including uncertainty in
all decision probabilities as well as several treatment cy-
cles for medical treatments and costs for procedures was
performed (see table 1). In addition, a Pearson’s correlation
coefficient between mean costs and number of different
possible pathways per centre was calculated, to estimate
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if complex treatment decision algorithms are correlated to
higher or lower costs.
Results
Our decision analytic model, modelling expected costs for
patients with recurrent GBM in eight different neuro-on-
cology centres in Switzerland demonstrated profound cost
differences when analysed from the Swiss healthcare payer
perspective with current pricing (May 2017, table 1).
In the base case analysis, mean costs per patient were dis-
tributed over a range from CHF 13,748 to CHF 22,072, be-
ing the lowest in centre 2 (CHF 13,748, 95% confidence
interval [CI] 9868–17,089) and the highest in centre 3
(CHF 22,072, 95% CI 21,414–22,639), which is 1.6 times
higher than in centre 2 (table 2).
Of the eight participating centres, five treated unfit patients
only with best supportive care. These centres showed the
largest difference in treatment costs, with a varying preva-
lence of fit versus unfit patients (fig. 1): Centres recom-
mending only best supportive care to unfit patients showed
an increase of mean costs per patient of CHF 14,829 to
CHF 22,785 for 0% versus 100% fit patients in the uni-
variate sensitivity analysis, whereas centres with tumour-
specific treatment options for unfit patients showed a cost
difference of CHF 694 to CHF 9132 between fit and unfit
patients (fig. 1). Interestingly, centre 1 had higher costs for
unfit patients than for fit patients. This can be explained
by the use of bevacizumab in unfit patients, whereas fit pa-
tients received only radiotherapy or surgery without sys-
temic therapy. Another factor strongly influencing overall
treatment costs in the strategy of the centres was the pro-
portion of patients with resectable tumours (fig. 2): sensi-
tivity analysis demonstrated differences in mean costs per
patient of up to CHF 17,120 depending on the prevalence
of 0% versus 100% resectable tumours.
The probabilistic sensitivity analyses showed that there
were considerable differences in the magnitude of cost dis-
tributions among the centres with centre 3 not only having
the highest costs but also the largest 95% CI and spread in
costs (figs 3 and 4).
Table 1: Costs, treatment duration and decision probability input parameters.
Treatment Scheme Unit price Absolute dose Costs per cycle Cycle
length
(weeks)
Number of
cycles
Distribution Reference
Bevacizumab 10 mg/kg every 2 weeks CHF 4.354/mg 700 mg
(patient 70 kg)
CHF 3048 + CHF
498 infusion
2 Median = 6
(range 1–30)
[10]
Gamma SL [26]
Clinical checks Blood count 1×/cycle
Urine 1× / 2 cycles
MRI 1× every 3 months
Temozolomide 200 mg/m2 days 1–5 CHF 0.6166/mg 1800 mg
(patient m2 =
1.77)
CHF 1110 4 Median = 3
(range 1–6)
[10]
Gamma SL [26]
Antiemetic (on-
dansetron)
1 tablet days 1–6 CHF 62.45 SL [26]
Clinical checks Clinical visit 1×/cycle
Blood count 4×/cycle
Visit for blood count
3×/cycle
MRI 1× every 3 months
Lomustine 4×40 mg CHF 0.897/mg 160 mg CHF 143.5 6 Median = 1
(range 1–6)
[10]
Gamma SL [26]
Antiemetic (on-
dansetron)
1 tablet/cycle 8 mg CHF 10.40 SL [26]
Clinical checks Blood count 6×/cycle
Visit for blood count
5×/cycle
Clinical visit 1×/cycle
MRI 1× every 3 months
Repeat surgery CHF 25,840 Triangular* Swiss DRG
[25]
Hypofractionated radio-
therapy
One course of 15×2.66
Gy over 3 weeks
CHF 9981 Triangular* Tarmed† [24]
Stereotactic fractionated
radiotherapy
One course of
6×5 Gy over 1 week
CHF 16,073 Triangular* Tarmed† [24]
Best supportive care CHF 250/week 4 Median = 6
(range 1–12)
Triangular Clinical esti-
mate
Clinical checks Clinical Visit CHF 379.00 Tarmed† [24]
MRI 1× every 3 cycles CHF 965.00 Tarmed† [24]
Blood count CHF 15.00 Tarmed† [24]
Urine test CHF 20.00 Tarmed† [24]
Visit for blood count CHF 69.00 Tarmed†
[24]
Probabilities for all deci-
sions
Mean = 0.5
95% CI
0.2–0.8
Beta
CI = confidence interval; MRI = magnetic resonance imaging; SL = Spezialitätenliste (official Swiss medication prices) * Triangular distribution with min = 0.75 and max = 1.25; †
Tarmed 1.08 BR version of Tarmed
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There was a significant correlation (R2 = 0.793, p = 0.019)
between the number of different treatment options at a cen-
tre and the average treatment costs, meaning that the more
complex the decision pathway and treatment options a cen-
tre provided, the more costly the average treatment was
(see supplementary fig. S1 in appendix 1).
Discussion
Recurrent or progressive GBM after primary therapy re-
mains a therapeutic challenge and there is currently no
standard of care [6], although various treatment options
have been developed in parallel [28]. We recently per-
formed a survey among eight Swiss neuro-oncology cen-
tres to assess and compare institutional treatment algo-
rithms for recurrent GBM [19], and for the vast majority of
scenarios a consensus was not identified.
Health economics is a topic of rising importance in oncol-
ogy [29] and has also been studied in the case of GBM [21,
30]. The introduction of novel therapeutic agents such as
temozolomide and bevacizumab increased treatment costs
from 2004 to 2008 in a French cohort study, but these in-
creases were considered cost-effective owing to improved
oncological outcome [31]. Likewise, temozolomide was
shown to be cost-effective in the treatment of newly diag-
nosed GBM [32, 33]. A Swiss study demonstrated that the
use of temozolomide in recurrent glioma is cost-effective
Table 2: Base case mean cost/patient in CHF.
Strategy Mean
(95% CI)
Incremental value 100% patients fit† 0% patients fit†
Centre 2* 13,748
(9868–17,089)
0 21,162 6333
Centre 1 14,292
(14,136–14,474)
545 13,945 14,639
Centre 7* 16,508
(11,184–21,206)
2216 26,682 6333
Centre 6* 16,700
(11,275–21,384)
192 27,066 6333
Centre 4* 16,825
(11,335–21,566)
125 27,316 6333
Centre 8* 17,726
(11,764–22,874)
901 29,118 6333
Centre 5 19,436
(17,047–21,500)
1710 24,002 14,870
Centre 3 22,072
(21,414–22,639)
2636 23,328 20,815
CI = confidence interval * Centres where unfit patients receive best supportive care only; † all other decision probabilities = 0.5
Figure 1: One-way sensitivity analysis expected base case mean costs per patient and centre by proportion of fit patients.* Centres were unfit
patients receive best supportive care only
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[22], which was confirmed by a systematic review of the
cost-effectiveness of temozolomide [34]. In contrary, a ret-
rospective patient cohort analysis from Canada suggested
that lomustine might be more cost-effective than temozolo-
mide in the treatment of recurrent GBM as a result of low-
er treatment costs and similar outcomes [35]. Bevacizum-
ab has been shown not to be cost-effective in the treatment
of newly diagnosed GBM [36], which can be primarily
explained by the lack of overall survival benefit in new-
ly diagnosed GBM as demonstrated in the AVAglio and
Figure 2: Univariate sensitivity analysis for all decision probabilities separately.
Figure 3: Probabilistic sensitivity analysis I, probable mean, median and 95% confidence interval costs per patient and centre.
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RTOG 0825 trials [37, 38]. Based on the recently present-
ed data of the EORTC 26101 trial, which showed a moder-
ate benefit in progression-free, but not overall, survival by
adding bevacizumab to lomustine in the treatment of recur-
rent GBM [11], it is also doubtful that its use may achieve
cost-effectiveness for recurrent disease. For repeat surgery
and re-irradiation of recurrent glioma, there are no cost-ef-
fectiveness data available.
Although there are very limited comparative outcome data
for the available therapies in recurrent GBM [6], we found
considerable cost differences among these treatment op-
tions in Switzerland (see table 1). In the base case scenario,
treatment costs varied between the centres by a factor of
1.6 from CHF 13,748 to CHF 22,072 (approximately USD
13,760 to 22,090 in May 2018) depending on the individ-
ual treatment algorithm.
Sensitivity analysis revealed that the distribution of two
patient characteristics particularly influenced the overall
institutional treatment costs: the proportion of patients
deemed “unfit” due to age, poor performance status or co-
morbidities [19], and the resectability of the tumour recur-
rence. Given the poor prognosis of elderly patients and pa-
tients with poor performance status [39], it may be justified
to withhold extensive tumour-directed therapies. Treat-
ment costs and potential side effects may outweigh the
benefits of any therapeutic intervention in this situation on
a group level from the view of the healthcare insurer. Be-
cause of the considerable contribution of repeated surgery
to overall treatment costs, careful patient selection is para-
mount: treatment decisions may be facilitated by scores as
published by Park et al. [40] taking into account tumour
volume, performance status, tumour location in non-elo-
quent areas and ependymal involvement. As there is very
little data directly comparing different treatment strategies
for GBM, it is not possible to correlate the varying treat-
ment costs with outcome. Our data show, however, the
considerable health economic consequences of different
interpretations of the available evidence and consequent
treatment choices. Additionally, our study serves as proof-
of-principle that centre-specific decision trees obtained by
the objective consensus methodology [20, 41] can be used
to estimate and to compare the average treatment costs of
different therapeutic algorithms. Especially in clinical sce-
narios such as recurrent GBM where there is no high-level
evidence for a superior oncological outcome with any ther-
apeutic strategy, treatment costs can be an important factor
in the medical decision making process.
However, there are several limitations to the study. First,
the analysis was based on the treatment recommendations
of the participating neuro-oncological centre without data
on the distribution of patient characteristics [19]. Conse-
quently, we performed a probabilistic sensitivity analysis
over a wide range of possible distributions of each patient
characteristic to investigate the possible cost distribution.
Centre-specific patient characteristics are needed for a
more accurate analysis of the economic impact of institu-
tional treatment algorithms.
Additionally, the survey did not include further therapies
after progression from second-line therapy or inclusion in-
to a prospective study as further treatment option. Sub-
sequent treatments after further progression and experi-
mental therapies are consequently not included into our
analysis, as they were not part of our survey [19] and high-
quality data were lacking [42]. However, different distrib-
Figure 4: Probabilistic sensitivity analysis II, proportion of patients by costs.
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utions of subsequent therapy lines depending on the treat-
ment at first recurrence could affect overall treatment costs
for each strategy and should therefore be reported for se-
ries of patients treated for recurrent glioblastoma. More-
over, we did not include costs for ambulatory care for out-
patients with poor performance as we assumed they might
be similar in all patients. Finally, we did not perform a
cost-effectiveness analysis owing to the lack of compara-
ble, unbiased outcome data for the different treatment op-
tions [6], as well as to the limited literature on health state
utilities in GBM, particularly for recurrent disease [43, 44].
In conclusion, our analysis of institutional treatment algo-
rithms of eight Swiss neuro-oncology centres study was
able to estimate the economic impact of individual ther-
apeutic strategies for recurrent GBM and demonstrated a
high variability in treatment costs among the centres.
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Appendix 1 Supplementary figure
Figure S1: Correlation between base case costs and number of treatment pathways.* Centres where unfit patients receive best supportive
care only.
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